MarketInOut Stock Screener Log In | Sign Up
 

Candel Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Candel Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization641.23 mln
Float61.34 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

22.11
Transformational upside

Relative Strength

13 / 100
Significantly lagging

Debt / Equity

0.39
Low leverage

ROE

-91.00
Deeply negative

ROA

-60.20
Deeply negative

Business Description

Candel Therapeutics is a clinical-stage company working to develop new treatments that use the immune system to fight cancer. Its pipeline includes two drug candidates currently in clinical trials ? one targeting prostate cancer and lung cancer, and another focused on a difficult-to-treat form of brain cancer. The company also operates a proprietary discovery platform based on modified herpes simplex virus technology, designed to generate new immunotherapy options for patients with solid tumors. Founded in 2003 and based in Needham, Massachusetts, Candel was previously known as Advantagene Inc.

Key Fundamentals

EPS-1.46
ROE-91.00
ROIC-764
ROA-60.20
Interest Cover-15.26
EBITDA, mln-83.14
EV / EBITDA-7.53
EV / EBIT-7.47

Quote Details

Last 8.03
Change -0.35 (-4.18%)
Open 8.33
Volume 1,157,738
Turnover 9,296,636
Average Volume 982,497

Financial Ratios

Leverage Ratio1.65
Current Ratio16.09
Price / Book6.29
Price / Tangible Book6.29
Debt / Equity0.39

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price22.11
Short Ratio11.02
Short % of Float21.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.95% 27 / 100   
1 Month -30.48% 11 / 100   
2 Months -16.09% 26 / 100   
6 Months 23.54% 90 / 100   
1 Year 52.66% 92 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog